Learn about the potential of low dose immunotherapy to revolutionize cancer care in India. We highlight how lower doses of drugs like nivolumab (Opdyta), pembrolizumab (Keytruda), and atezolizumab (Tecentriq) are playing a key role in reducing treatment costs, which patients typically have to pay out-of-pocket. This allows patients to receive the same treatment at low cost, and prices can be reduced by 90-95%. With this, every patient can now access the expensive injections and pills of immunotherapy.
We also explain the role of the clinical trials that made low-dose immunotherapy possible, and the importance of patient support in managing side effects. Through our analysis from Delhi, we highlight the latest advances in oncology research, emphasizing that these strategies are not only affordable but also effective. Learn from Delhi's renowned Cancer Specialist Medical Oncologist Dr. Vineet Govinda Gupta MBBS (AIIMS) , MD (AIIMS), DM (AIIMS), Gold Medalist.
If you have any question other than this video contact us on whatsapp, phone, or email. Subscribe to our channel.

Phone: +919013812875, +917290928042
Website: http://drvineetgovinda.com
E-Mail: [email protected]
Facebook: @drvineetgovindagupta
Twitter: @drvineetgovinda

00:00 Introduction परिचय
01:08 What is cancer immunotherapy कैंसर इम्मुनोथेरपी क्या होती है
01:58 What is low dose immunotherapy लौ डोज़ इम्मुनोथेरपी क्या होती है
02:52 Evidence behind low dose immunotherapy लौ डोज़ इम्मुनोथेरपी के सबूत
05:21 Experience with low dose immunotherapy लौ डोज़ इम्मुनोथेरपी का हमारा तजुर्बा
05:48 Low dose vs Full dose immunotherapy लौ या पूरा डोज़ इम्मुनोथेरपी में कौनसा लेना चाहिए
08:30 Dangers of low dose immunotherapy लौ डोज़ इम्मुनोथेरपी के खतरे
09:18 Contact information संपर्क